NCT07464522

Brief Summary

The goal of this observational study:

  • To evaluate the diagnostic accuracy of non-invasive markers in predicting the presence and grading of esophageal varices in children with portal hypertension.
  • To correlate these non-invasive markers with the severity of portal hypertension and the grade of esophageal varices to identify patients at high risk of bleeding.
  • To propose a defined protocol for screening esophageal varices in those children.

Trial Health

65
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
51

participants targeted

Target at P25-P50 for all trials

Timeline
23mo left

Started Mar 2026

Typical duration for all trials

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress11%
Mar 2026May 2028

First Submitted

Initial submission to the registry

March 2, 2026

Completed
9 days until next milestone

First Posted

Study publicly available on registry

March 11, 2026

Completed
9 days until next milestone

Study Start

First participant enrolled

March 20, 2026

Completed
2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 20, 2028

Expected
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 20, 2028

Last Updated

March 23, 2026

Status Verified

March 1, 2026

Enrollment Period

2 years

First QC Date

March 2, 2026

Last Update Submit

March 19, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Area Under the Receiver Operating Characteristic (AUROC) Curve of non-invasive markers for predicting esophageal varices in children with portal hypertension

    The AUROC will be used as the aggregate reported value to represent the diagnostic performance of the following markers: platelet count, spleen size z-score, platelet-to-spleen ratio, AST-to-Platelet Ratio Index (APRI), FIB-4 score, and King score. Using the AUROC combines sensitivity and specificity across all possible cut-off values into a single statistical measure of diagnostic accuracy for predicting the presence and grade of esophageal varices. Esophagogastroduodenoscopy (EGD) will serve as the reference (gold standard) method for detecting and grading esophageal varices.

    Baseline

Secondary Outcomes (1)

  • Correlation between non-invasive markers and endoscopic grade of esophageal varices in children with portal hypertension

    Baseline

Eligibility Criteria

AgeUp to 18 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64)
Sampling MethodNon-Probability Sample
Study Population

Portal hypertension in children will be defined using non-invasive clinical, laboratory, and Doppler-ultrasound criteria, in the context of clinical presentation, without invasive pressure measurements. Patients with portal hypertension will be classified as: patients with hepatic causes and patients with extrahepatic causes All patients included in this study will be subjected to: * 1\. Full Clinical History * 2\. Detailed Clinical Examination * 3\. Laboratory Investigations * 4\. Abdominal Ultrasound * 5\. Doppler Ultrasound * 6.Non-invasive predictive scores for esophageal varices The following parameters will be assessed: * Platelet count (PLT) * Spleen size z-score * Platelet count to spleen size ratio: * CPR (Calculated Platelet Ratio) * APRI (AST to Platelet Ratio Index) * FIB-4 * King score * MELD and PELD scores will be analyzed as secondary variables and not as primary predictors of esophageal varices -7. Esophagogastroduodenoscopy (EGD)

You may qualify if:

  • Patients aged less than 18 years diagnosed with portal hypertension either due to hepatic or extrahepatic causes

You may not qualify if:

  • Active variceal bleeding at presentation (hemodynamic instability affects platelet/spleen parameters).
  • Previous history of variceal bleeding or endoscopic intervention (band ligation/sclerotherapy).
  • Prior surgical portosystemic shunts or Transjugular Intrahepatic Portosystemic Shunt (TIPS).
  • Current use of vasoactive drugs for primary prophylaxis (e.g., Non-selective beta-blockers).
  • Systemic infections or hematological disorders causing independent thrombocytopenia or splenomegaly (to avoid confounding the platelet/spleen ratio).

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Esophageal and Gastric VaricesHypertension, Portal

Condition Hierarchy (Ancestors)

Esophageal DiseasesGastrointestinal DiseasesDigestive System DiseasesLiver Diseases

Central Study Contacts

Mennat-Allah H Abdelraheem, MD

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Lecturer of Pediatrics

Study Record Dates

First Submitted

March 2, 2026

First Posted

March 11, 2026

Study Start

March 20, 2026

Primary Completion (Estimated)

March 20, 2028

Study Completion (Estimated)

May 20, 2028

Last Updated

March 23, 2026

Record last verified: 2026-03

Data Sharing

IPD Sharing
Will not share